{"entity":{"id":"nct07259590","kind":"trial","name":"A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation","aka":[],"tldr":"A phase 1/2 trial of GFH375, Cetuximab, Paclitaxel / nab-paclitaxel in colorectal cancer, run by Genfleet Therapeutics (Shanghai) Inc., now recruiting.","summary":"A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation is a phase 1/2 interventional study registered as NCT07259590 by Genfleet Therapeutics (Shanghai) Inc., with 126 participants planned, started 2025-10-21 and due to reach its primary completion in 2027-07. Interventions recorded: GFH375, GFH375. Conditions listed: Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07259590","url":"https://clinicaltrials.gov/study/NCT07259590"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal","kras-g12c-colorectal"],"sections":[],"technologies":["monoclonal-antibody"],"targets":[],"drugs":["gfh375","cetuximab","paclitaxel","gemcitabine"],"companies":["genfleet"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07259590","phase":"1/2","setting":"A Multicenter, Open-Label, Phase Ib/II Clinical Study to Explore the Efficacy, Pharmacokinetics and Safety/Tolerability of GFH375 in Combination With Cetuximab or Chemotherapy in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutation","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","participation":[{"nct":"NCT07259590","source":"https://clinicaltrials.gov/study/NCT07259590","fetchedAt":"2026-10-07T16:55:36.272Z","studySha256":"f07334da3b131208a11821aec71d86fe0dc6636e20ab50c6e9447c102312a099","overallStatus":"RECRUITING","lastUpdatePosted":"2025-12-02","leadSponsor":"Genfleet Therapeutics (Shanghai) Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":126,"enrolmentType":"ESTIMATED","siteCount":4,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-10-21","startedType":"actual","enrolled":126,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07259590/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"gfh375","kind":"drug","name":"GFH375","route":"/drugs/gfh375/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"company":[{"id":"genfleet","kind":"company","name":"GenFleet Therapeutics","route":"/companies/genfleet/"}]}}